The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersNeurobiology of suicidal behavior in post-traumatic stress disorderAmygdala FAAH and anandamide: mediating protection and recovery from stressTranslational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorderElevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography studyDevelopmental regulation of fear learning and anxiety behavior by endocannabinoids.Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate DiscussedAn Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical TrialsInteraction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retentionCannabinoids prevent the effects of a footshock followed by situational reminders on emotional processing.Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress.Glucocorticoids interact with the hippocampal endocannabinoid system in impairing retrieval of contextual fear memory.Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdalaPTSD and Cannabis-Related Coping Among Recent Veterans in New York City.Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.Sleep disturbances as the hallmark of PTSD: where are we now?Clinical applications of hallucinogens: A review.Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder.Replication and expansion of "Best Practice Guide for the Treatment of Nightmare Disorder in Adults".Childhood trauma, PTSD, and problematic alcohol and substance use in low-income, African-American men and women.Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1.Marijuana dependence moderates the effect of posttraumatic stress disorder on trauma cue reactivity in substance dependent patientsThe endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnessesStress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure.Latest advances in cannabinoid receptor agonists.Sleep in psychiatric disorders: where are we now?PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.Investigational drugs under development for the treatment of PTSD.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review.Cannabis, Cannabinoids, and Sleep: a Review of the Literature.Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment.Erratum: Targeting the endocannabinoid system to treat haunting traumatic memories.
P2860
Q22299116-E185BFE8-2F5E-4727-811F-5EF5AAE0A804Q22305928-1A406074-55ED-4197-A3F0-1514090F6093Q27026443-37515CAE-4869-4557-85C0-710D7DBFB06DQ27026926-14EEC332-88ED-4866-8EE3-93ED07601413Q28290553-FBF91D6C-F9C9-475F-956C-8C00094E0465Q30366747-2BADE882-2E91-4AE9-91DF-6084C3787E04Q30366949-6C58D3CC-F41E-43F7-96DF-012266AE91C6Q30375098-E20A02B7-7E37-4A90-9F77-44498058ECC8Q30392035-7CA2D033-7F05-4984-9285-B60379C15E6DQ30400006-F6E0C1C4-DA11-471B-B648-71D00481873EQ30459626-4F9FDCBA-8FA5-49E5-8F6C-3351CABDE904Q30464452-2082DFF0-BDF6-4827-9406-FAE66021E761Q30498563-C16104D1-9DFC-4AEE-ABAB-27E47198CA12Q33810814-04B9BDC2-B8BE-4053-9261-1B05DF4A8F39Q34194009-259DF83A-3358-4946-B7B1-34627B35D84EQ34342884-663AB4BA-A58F-457A-A1A6-E32491F81EF9Q34535259-79ED9C06-7425-4F7F-BD6C-C8CDC0D2BC0AQ34717660-50C13075-3B43-4975-97ED-53FC34B2DE7BQ35311720-F970B7D4-FEDD-446E-ABD0-8D88707F702BQ35706774-48F0C2AD-9DD9-4EA4-8558-CC4383746657Q35738226-F310FA27-7D76-4DCE-B585-A02BD355DF17Q35784024-8292FA6E-6015-4199-B716-411560E3ED82Q36234238-EE602DB9-AAA3-4F51-8094-268C873A4DA2Q36417706-E7622BA5-8AB3-4F54-A785-1816AEE9283AQ36589751-99A61F0B-6B61-4556-AAC8-B1CEC40DDC21Q36938853-825AE521-5630-4ABC-A769-85F08ED5CC77Q37083923-A492E342-2C8E-46B9-9A91-20C05A0F8A7EQ37279826-1A4E4839-DA12-4F3D-8947-88D0B23ED8BEQ37529127-56D1D25B-807E-4682-831D-E8D557B60213Q37638736-F9960CF0-7F46-4E0B-BEF5-EE6E6108B11BQ37779583-E08E27DA-24FF-4855-8D6E-AE3CA1FEEE2FQ38211890-7CA2272C-D918-4805-B69F-6140C78E592DQ38378939-8031E776-3CD6-4CFB-8D0D-B193075D0BD0Q38503842-9D854E8D-B890-4123-8FB1-71168117E0D7Q39154540-259374D4-E954-495F-9A1F-E8837FBF4788Q39204199-9C8676E8-80E0-4333-84F5-6FCC6B5B6896Q39388243-9605E0B2-9AD4-4E79-9999-4FA4FFA6A9E7Q39459073-5C6ADFBB-4998-4AD5-ABF8-DD6C7B43000CQ41319332-317F0BFC-9F89-4E4F-AD61-EA22E3FB7941Q42635177-0583A16E-3DC3-4C23-AAA8-EFC8C9CE7326
P2860
The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@ast
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@en
The use of a synthetic cannabi ...... posttraumatic stress disorder
@nl
type
label
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@ast
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@en
The use of a synthetic cannabi ...... posttraumatic stress disorder
@nl
prefLabel
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@ast
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@en
The use of a synthetic cannabi ...... posttraumatic stress disorder
@nl
P921
P1476
The use of a synthetic cannabi ...... umatic stress disorder (PTSD).
@en
P2093
George A Fraser
P2860
P356
10.1111/J.1755-5949.2008.00071.X
P577
2009-01-01T00:00:00Z